

In the Claims

1-11 (canceled).

12 (currently amended). A method for the reduction and/or treatment of gamete numerical chromosomal alterations in a male, comprising the administration of a ~~pharmaceutically active~~ an effective amount of FSH or FSH variant to ~~the male in need thereof~~ a male having gamete numerical chromosomal alterations, wherein the effective amount is sufficient to reduce or treat the rate of gamete numerical chromosomal alteration in the male.

13 (canceled).

14 (currently amended). The method according to ~~claim 13~~ claim 12, wherein the gamete numerical chromosomal alteration is spermatozoa diploidy.

15 (currently amended). The method according to ~~claim 13~~ claim 12, wherein the gamete numerical chromosomal alteration is sexual chromosome disomy.

16 (previously presented). The method according to claim 12, wherein the male is human.

17 (previously presented). The method according to claim 12, wherein the substance is FSH.

18 (previously presented). The method according to claim 12, wherein the substance is rFSH.

19 (previously presented). The method according to claim 12, wherein the substance is administered on alternate days.

20 (previously presented). The method according to claim 12, wherein the substance is administered at or about 75 to 300 IU/dose.

21 (previously presented). The method according to claim 12, wherein the substance is administered at or about 150 IU/dose.

22 (previously presented). The method according to claim 12, wherein the substance is rFSH and the human male is suffering from gamete aneuploidy.

23 (previously presented). The method according to claim 22, wherein the substance is administered on alternate days.

24 (previously presented). The method according to claim 23, wherein the substance is administered at or about 75 to 300 IU/dose.

25 (previously presented). The method according to claim 24, wherein the substance is administered at or about 150 IU/dose.

26 (previously presented). The method according to claim 19, wherein the substance is administered at or about 75 to 300 IU/dose.

27 (previously presented). The method according to claim 26, wherein the substance is administered at or about 150 IU/dose.

28 (previously presented). The method according to claim 12, wherein said variant FSH is CTP-FSH, single chain CTP-FSH or a FSH glycosylation variant.

29 (previously presented). The method according to claim 12, wherein said male is a human and said gamete chromosomal alteration is spermatozoa diploidy.